Peripheral Determinants of Oxygen Utilization in Heart Failure With Preserved Ejection Fraction by Zamani, Payman et al.
Northumbria Research Link
Citation: Zamani, Payman, Proto, Elizabeth A., Mazurek, Jeremy A., Prenner, Stuart B., Margulies, 
Kenneth B., Townsend, Raymond R., Kelly, Daniel P., Arany, Zoltan, Poole, David C., Wagner, Peter 
and Chirinos,  Julio A.  (2020) Peripheral  Determinants of  Oxygen Utilization in Heart  Failure With 
Preserved Ejection Fraction. JACC: Basic to Translational Science, 5 (3). pp. 211-225. ISSN 2452-
302X 
Published by: Elsevier
URL: https://doi.org/10.1016/j.jacbts.2020.01.003 <https://doi.org/10.1016/j.jacbts.2020.01.003>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/44627/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        

J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E VO L . 5 , N O . 3 , 2 0 2 0
ª 2 0 2 0 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .CLINICAL RESEARCHPeripheral Determinants of
Oxygen Utilization in Heart Failure
With Preserved Ejection Fraction
Central Role of AdiposityPayman Zamani, MD, MTR,a Elizabeth A. Proto, BA,a Jeremy A. Mazurek, MD,a Stuart B. Prenner, MD,a
Kenneth B. Margulies, MD,a Raymond R. Townsend, MD,b Daniel P. Kelly, MD,a Zoltan Arany, MD, PHD,a
David C. Poole, PHD, DSC,c Peter D. Wagner, MD,d Julio A. Chirinos, MD, PHDaISSN 2452-302X
From the aDivision of Cardio
of Nephrology/Hypertensio
ments of Kinesiology, Anat
Medicine, University of CaliVISUAL ABSTRACTv
n,
om
foZamani, P. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(3):211–25.https://doi.org/10.1016/j.jacbts.2020.01.003
ascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; bDivision
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; cDepart-
y, and Physiology, Kansas State University, Manhattan, Kansas; and the dDivision of Pulmonary
rnia-San Diego, San Diego, California. The project described was supported by the National Center
ABBR EV I A T I ON S
AND ACRONYMS
CO = cardiac output
DAVO2 = arteriovenous oxygen
content difference
DEXA = dual-energy x-ray
absorptiometry
DmO2 = skeletal muscle
diffusional conductance for
oxygen
FIO2 = fraction of inspired
oxygen
HFpEF = heart failure with
preserved ejection fraction
MVC = maximal voluntary
contraction force
NT-proBNP = N-terminal pro–
brain natriuretic peptide
PO2 = partial pressure of
oxygen
VO2 = oxygen consumption
for Researc
grant UL1T
has receive
supported
Merck (sign
R01 HL1283
NIH grant
ported by N
R56-HL136
The author
stitutions a
the JACC: B
Manuscript
Zamani et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 5 , N O . 3 , 2 0 2 0
DAVO2 in HFpEF M A R C H 2 0 2 0 : 2 1 1 – 2 5
212HIGHLIGHTS
 DAVO2 during exercise is a complex metric that incorporates into its calculation skeletal muscle blood flow and
DmO2 across the skeletal muscle capillary membrane.
 Although DAVO2 was reduced in patients with HFpEF during both systemic and local (forearm) exercise, there
was no difference in forearm DmO2 among subjects with HFpEF, those with hypertension, and healthy control
subjects; therefore, abnormalities in forearm DmO2 cannot explain the reduced forearm DAVO2 seen in subjects
with HFpEF.
 Local forearm exercise performance predicted about one-third of the variability in systemic aerobic capacity,
demonstrating that peripheral factors are important in determining whole-body exercise tolerance.
 Degree of adiposity strongly correlated with DAVO2 during both local and whole-body exercise, suggesting that
adipose tissue may play an active role in limiting exercise capacity in subjects with HFpEF.SUMMARYh R
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reThe aim of this study was to determine the arteriovenous oxygen content difference (DAVO2) in adult subjects
with and without heart failure with preserved ejection fraction (HFpEF) during systemic and forearm exercise.
Subjects with HFpEF had reduced DAVO2. Forearm diffusional conductance for oxygen, a lumped conductance
parameter that incorporates all impediments to the movement of oxygen from red blood cells in skeletal
muscle capillaries into the mitochondria within myocytes, was estimated. Forearm diffusional conductance for
oxygen was not different among adults with HFpEF, those with hypertension, and healthy control subjects;
therefore, diffusional conductance cannot explain the reduced forearm DAVO2. Instead, adiposity was strongly
associated with DAVO2, suggesting an active role for adipose tissue in reducing exercise capacity in patients
with HFpEF. (J Am Coll Cardiol Basic Trans Science 2020;5:211–25) © 2020 The Authors. Published by Elsevier
on behalf of theAmerican College of Cardiology Foundation. This is an open access article under the CCBY-NC-ND
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213mitochondria (“diffusive transport”) (8). Because
slower blood flow through the capillary can lead to
greater oxygen extraction because of longer capillary
transit time, DAVO2 is not dependent solely on skel-
etal muscle properties (7). In contrast, skeletal muscle
diffusional conductance for oxygen (DmO2) is a
lumped parameter that summarizes all impediments
to the transfer of oxygen from red blood cells into
mitochondria, accounting for differences in blood
flow. Thus, DmO2 is a purer reflection of skeletal mus-
cle properties than DAVO2, incorporating features
such as capillarity, fiber size, and fiber composition
into its determination. An assessment of DmO2 is
essential to help resolve the mechanistic basis for
the deficits in DAVO2 seen in patients with HFpEF.
We determined forearm DmO2 in adults with
HFpEF and control subjects using an exercise para-
digm that engages the small muscle mass of the
forearm and therefore is not constrained by limita-
tions in cardiac output (CO) (9). We hypothesized that
subjects with HFpEF would exhibit lower DmO2,
explaining their DAVO2 abnormalities. Contrary to our
hypothesis, we did not find reductions in forearm
DmO2 in subjects with HFpEF. Instead, we found the
degree of adiposity to be a key correlate of DAVO2,
supporting a deleterious role of body fat per se in
patients with HFpEF and suggesting a novel mecha-
nistic link between obesity and the limitations in
aerobic capacity in patients with HFpEF.
METHODS
PARTICIPANTS. This was a cross-sectional analysis
of subjects with HFpEF, patients with hypertension
without heart failure symptoms, and healthy control
subjects. Inclusion criteria for subjects with HFpEF
included symptomatic heart failure (New York Heart
Association functional class II or III) in the context of
a preserved ejection fraction ($50%) and stable
medical management for at least 1 month. Subjects
were required to have evidence of elevated filling
pressure, which included at least 1 of the following: 1)
prior admission for heart failure requiring intrave-
nous diuretic agents; 2) history of elevated invasively
determined filling pressures (pulmonary capillary
wedge pressure >15 mm Hg or left ventricular end-
diastolic pressure >16 mm Hg); 3) mitral E/septal e0
ratio >15; or 4) mitral E/e0 ratio >8 in addition to 1 of
the following: elevated N-terminal pro–brain natri-
uretic peptide (NT-proBNP), left atrial volume index
>34 ml/m2, or chronic use of loop diuretic agents for
control of heart failure symptoms. Given the near
ubiquitous presence of hypertension in patients with
HFpEF, we enrolled a group of patients withhypertension without heart failure symptoms as an
additional control group. Patients with hypertension
included those who were treated with antihyperten-
sive medications, had been on stable medical therapy
for at least 1 month, and had no histories or symptoms
consistent with heart failure. Healthy control subjects
were those who did not have histories of hyperten-
sion or heart failure. Although other cardiovascular
conditions were exclusionary, treated hypercholes-
terolemia was allowed in the healthy group to allow
representation of elderly subjects within the healthy
control group. Exclusion criteria were as follows:
current atrial fibrillation; inability to exercise; mod-
erate or greater aortic or mitral valve disease;
hemoglobin <10 g/dl; known hypertrophic, inflam-
matory, or infiltrative cardiomyopathy; pericardial
disease; current angina due to clinically significant
obstructive epicardial coronary disease; acute coro-
nary syndrome within the past 2 months; primary
pulmonary arterial hypertension; clinically signifi-
cant lung disease (e.g., current use of supplemental
oxygen aside from nocturnal oxygen as part of treat-
ment for obstructive sleep apnea, use of steroids or
antibiotics within the past 6 months for an acute
exacerbation of obstructive pulmonary disease, most
proximal pulmonary function testing with a forced
expiratory volume in 1 s <50% predicted, and most
proximal 6-min walk test with arterial oxygen desa-
turation); ischemia on stress testing without subse-
quent revascularization or demonstration of
nonobstructive coronary disease on coronary angi-
ography; significant liver disease affecting synthetic
function or volume control; uncontrolled hyperten-
sion (blood pressure >180/110 mm Hg at baseline),
estimated glomerular filtration rate <30 ml/min/m2 or
creatinine >2.5 mg/dl; alcohol dependence; and
chronic narcotic use that could not be interrupted.
The University of Pennsylvania Institutional Review
Board approved the study. All subjects provided
written informed consent prior to entry.
STUDY PROCEDURES. Subjects presented to the
Center for Human Phenomic Science at the University
of Pennsylvania in a fasting state. Blood was obtained
for basic chemistry, complete blood count, and NT-
proBNP measurement (Cobas e411 Analyzer, Roche
Diagnostics, Indianapolis, Indiana). One heart failure
cardiologist (P.Z.) reviewed themedical history of each
subject, and anthropomorphic data were collected.
DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA).
Whole-body DEXA was performed for body composi-
tion on a Hologic Horizon scanner (analysis version
13.5.3.1, Hologic, Bedford, Massachusetts). Whole-
body (fat mass, lean mass [including lean mass plus
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and limb-specific composition data were obtained.
ECHOCARDIOGRAPHY AND HEMODYNAMIC MEA-
SUREMENTS. Subjects underwent resting and exer-
cise echocardiography using a GE Vivid E9 machine
(GE Healthcare, Fairfield, Connecticut). The left ven-
tricular outflow tract Doppler velocity-time integral
was obtained from the 5-chamber view at rest and
during exercise. Stroke volume was calculated as the
product of the left ventricular outflow tract velocity-
time integral and its cross-sectional area; CO was
calculated as stroke volume  heart rate (10,11).
EXERCISE PROTOCOL. As described previously,
subjects underwent a maximal-effort supine exercise
test using cycle ergometry with gas exchange mea-
surements (Parvo Medics, Sandy, Utah) (10,11). Work
rate began at 15 W for 3 min, increasing to 25 W for
3 min, then increasing by 25 W every 3 min thereafter.
A metronome was used to maintain a cadence of
60 rpm. The exercise test was terminated either at the
time of volitional fatigue or when the cadence could
not be maintained above 50 rpm, despite strong ver-
bal encouragement. In a prior study using an identical
protocol, our subjects with HFpEF were able to ex-
ercise for approximately 15 min (10). After completion
of the 125-W stage (18 min), the duration of each stage
for patients with hypertension and healthy subjects
was reduced to 2 min to speed completion of
the protocol.
Custom-designed software was programmed in
MATLAB version R2016b (The MathWorks, Natick,
Massachusetts) for processing and quantification of
cardiopulmonary exercise testing data. Breath-by-
breath measurements were passed through a low-
pass frequency filter to remove random noise in the
measurements. Baseline measurements were
obtained from the minute prior to the initiation of
exercise. Peak oxygen consumption (VO2) and other
gas-exchange measurements were defined as the
average values obtained during the last 30 s of exer-
cise. Peak predicted VO2 was calculated using the
Wasserman/Hansen equations (12). Respiratory ex-
change ratio was calculated as the ratio of carbon
dioxide production to VO2 at peak exercise. Heart rate
was monitored throughout exercise using a 12-lead
electrocardiographic system (XScribe 5, Mortara In-
struments, Milwaukee, Wisconsin). Systemic DAVO2
was determined as the ratio of VO2 to CO. A venous
blood gas sample was obtained from a standard
indwelling antecubital catheter at the end of the cycle
ergometric exercise protocol. An arterial blood gas
sample was obtained from the radial artery at peak
exertion, immediately after the cessation of cycleexercise (generally within 10 s of exercise cessation).
Blood gas samples throughout the protocol were
analyzed using a GEM Premier 4000 automated
analyzer (Instrumentation Laboratory, Bedford,
Massachusetts). Values were measured at 37C. Blood
pressure was measured throughout exercise using a
validated oscillometric device (Tango M2 blood
pressure monitor, SunTech Medical Instruments,
Morrisville, North Carolina) (13). Peripheral vascular
resistance was computed as mean arterial pressure/
CO and expressed in Wood units. Pulmonary vascular
resistance was also indexed to body surface area to
account for differences in body size (14).
FOREARM EXERCISE PROTOCOL. Following cycle
ergometric exercise, subjects were provided with a
standardized meal. Approximately 1 h later, a 20-
gauge, 1-inch venous catheter (BD Insyte Autoguard
BC shielded intravenous catheter, Becton Dickinson
Infusion Therapy Systems, Sandy, Utah) was inserted
into a deep antecubital vein of the dominant arm,
ensuring that the vein selected did not take a super-
ficial course but rather went deep into the muscle, by
visual inspection (15).
A grip-force transducer (linear range: 0–800 N;
accurate to within 5%) was connected to a PowerLab
data acquisition module (ADInstruments, Colorado
Springs, Colorado) running LabChart Pro on a
Macintosh personal computer. Subjects performed 3
maximal-effort 1-s isometric handgrip contractions,
with the peak force output (newtons) averaged to
determine maximal voluntary contraction force
(MVC). Subjects then began a graded forearm exercise
protocol during which they performed handgrip ex-
ercise at 40% MVC for 1 min, increasing immediately
thereafter to exercise at 50% MVC for 1 min, and then
maximal effort for 1 min. Contractions were sustained
at a given force for 1 s followed by 2 s of rest (0.33 Hz).
A combination of visual and auditory cues was used
to maintain cadence and grip strength. During the
final 15 s of each stage, deep venous blood was drawn
into a heparinized blood gas syringe, placed on ice,
and immediately run on the blood gas analyzer.
Forearm handgrip data (average %MVC and total
work performed) was automatically abstracted by the
LabChart software for the final 20 s of each exercise
increment.
Brachial artery blood flow was assessed using a
vascular probe at rest and during the last 15 s of each
exercise transient. Doppler velocity profiles of
contraction-relaxation cycles, each lasting 3 s in
duration, were obtained at each stage of exercise.
Time-averaged mean velocities for each contraction-
relaxation cycle were automatically traced using the
FIGURE 1 DmO2 Method
A forward integration is performed during which the changes in oxygen and carbon dioxide content are simultaneously calculated along each
step of the capillary. Skeletal muscle diffusional conductance for oxygen (DmO2) is iteratively varied until the end-capillary contents match
the measured venous blood gas contents for oxygen and carbon dioxide. pCO2 ¼ partial pressure of carbon dioxide; pO2 ¼ partial pressure of
oxygen.
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215Vivid E9 ultrasound system. Vessel diameter was
measured at end-diastole at the same vessel location
at which Doppler velocities were obtained. Brachial
artery blood flow was determined as the product of
the average mean velocity and the vessel cross-
sectional area (Figure 1).
After 30 min of rest, the forearm exercise protocol
was repeated. To demonstrate that peak forearm ex-
ercise performance was limited by oxygen delivery
and not by mitochondrial oxidative capacity,additional studies were performed while breathing
100% oxygen (FIO2 ¼ 1.00) to increase arterial oxygen
content (9,16). Following 30 min of rest after the
room-air transients (FIO2 ¼ 0.21), 2 additional iden-
tical exercise transients were then performed while
the subject breathed 100% oxygen. Two room-air
forearm exercise bouts were always performed first,
followed by 2 exercise bouts while breathing 100%
oxygen. Within a given FIO2 (0.21 or 1.00), there was
no significant difference in work performed, brachial
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216flow, or forearm VO2 at maximal exertion; therefore,
results from the 2 transients at each FIO2 were aver-
aged together to minimize variation.
A resting arterial blood gas sample was obtained
once at each FIO2. Given the minimal demand of
forearm exercise on whole-body exercise capacity,
the arterial content was assumed to be constant
throughout each forearm exercise transient (17).
Venous blood sampling from a deep vein has previ-
ously been shown to reflect forearm muscle metabolic
activity during handgrip exercise, as evidenced by a
commensurate rise in VO2 with exercise (17–19).
Arterial and venous oxygen contents were deter-
mined as: 1.34  hemoglobin (g/dl)  oxygen satura-
tion/100 þ 0.003  partial pressure of oxygen (PO2)
(mm Hg). Forearm VO2 was determined as DAVO2
multiplied by brachial artery blood flow.
DETERMINATION OF FOREARM DmO2. In brief, a
numeric integration procedure was performed such
that, starting with arterial oxygen and carbon dioxide
contents, the contents of both gases in capillary blood
are incrementally changed as oxygen and carbon di-
oxide are exchanged across the capillary membrane
in small time steps. For any given blood flow, the rate
of movement across the membrane is governed by the
diffusional conductance for the specific gas, where
the diffusional conductance for carbon dioxide is
assumed to be 20 times DmO2. The procedure is
repeated iteratively, using different estimates for
DmO2, until the calculated oxygen and carbon dioxide
contents at the end of the skeletal muscle capillary
match the directly measured venous blood gas con-
tents (Figure 1) (see the Supplemental Appendix for
additional details on methodology) (9,20,21).
STATISTICAL ANALYSIS. Demographic data are pre-
sented as count (percentage), mean  SD, or median
(interquartile range). The Shapiro-Wilk test was used
to assess normality. Variables with skewed distribu-
tions were compared using the Kruskal-Wallis test,
and normally distributed variables were compared
using analysis of variance. Post hoc comparisons for
between-group differences were performed with
Bonferroni correction. Average values from the
overall cohort were recorded for both room-air
(FIO2 ¼ 0.21) and FIO2 ¼ 1.00 oxygen transients.
When a significant difference between FIO2 ¼ 0.21 and
FIO2 ¼ 1.00 was detected for a given outcome variable,
intergroup differences in the change were compared
to assess for differences in the group response to
oxygen. Linear mixed-effect models with random
intercepts were created using all available data points
(FIO2 ¼ 0.21 and FIO2 ¼ 1.00) from the forearm exercise
studies to examine relationships between thedeterminants of VO2 using the Fick principle. The
mixed package from STATA/SE version 13.1 (Stata-
Corp., College Station, Texas) was used, assuming an
independent covariance structure.
In these models, estimated marginal means of
brachial flow indexed to forearm lean muscle were
computed to adjust for differences in muscle mass.
Analogous models were also created using systemic
parameters to assess the change in systemic DAVO2 as
a function of the change in estimated marginal means
of CO, indexed to total leg lean mass. We analyzed the
relationships between body composition and local
and systemic DAVO2 using ordinary least squares
linear regression. Additional covariates with biologic
plausibility were tested within the model, including
age, sex, HFpEF status, forearm DmO2, and blood
flow (brachial artery flow or CO for local and systemic
models, respectively). Parsimonious models were
created using backward elimination to remove vari-
ables that did not significantly contribute to the pre-
diction. Standardized beta values are presented,
expressing the change in the dependent variable for
each 1-SD change in the independent variable,
allowing meaningful comparison of the strength of
associations among independent variables in a unit-
less manner. Ordinary least squares linear regression
models were also created to examine the relationship
between forearm and cycle ergometric VO2. Within
this regression model, interaction testing was per-
formed to determine if the slope in the relationship
between forearm VO2 and cycle ergometry was
different between groups. The interaction was not
significant and was not included in the final model.
The adjusted R2 values for the multivariate ordinary
least squares linear regression models are presented,
describing the proportion of variability of the
dependent variable that is explained by the cova-
riates. Spearman’s rho was used to measure the
strength of associations between variables. Analyses
were performed in STATA/SE version 13.1, with p
values <0.05 considered to indicate statistical sig-
nificance. One author (P.Z.) had access to all data and
takes responsibility for its integrity and data analysis.
RESULTS
STUDY POPULATION. Fifty-nine subjects (20
healthy, 19 with hypertension, 20 with HFpEF) were
enrolled in the study and provided exercise data. All
subjects with HFpEF were symptomatic. Three sub-
jects with HFpEF were enrolled on the basis of his-
tories of heart failure hospitalization, 11 were enrolled
on the basis of elevations in invasively measured
intracardiac filling pressures, 3 were enrolled on the
TABLE 1 Subject Characteristics
Healthy (n ¼ 20) HTN (n ¼ 19) HFpEF (n ¼ 20) p Value
Age, yrs 54 (39–63) 66 (50–71) 67* (62–76) 0.001
Female 6 (30) 7 (37) 13 (65) 0.067
Ethnicity 0.001
White 20 (100) 14 (73.7) 12 (60)
African American 0 (0) 3 (15.8) 8 (40)
Asian 0 (0) 2 (10.5) 0 (0)
Height, cm 171.9  6.8 171.6  9.7 165.3  9.9 0.037
Weight, kg 81.4 (68.7–85.7) 80.4 (73.0–89.0) 99.1* (78.3–113.5) 0.020
BMI, kg/m2 26.7 (23.6–28.7) 27.7 (24.6–31.5) 32.1*† (28.7–44.4) <0.001
Total body fat, % 30.8  9.0 34.2  9.4 43.3  7.3*† <0.001
Total body lean mass, % 69.2  9.0 65.8  9.4 56.7  7.3*† <0.001
Forearm total mass, kg 1.23 (1.04–1.37) 1.24 (1.13–1.37) 1.24 (1.00–1.49) 0.81
Forearm lean mass, kg 0.89 (0.66–1.03) 0.92 (0.61–1.06) 0.60 (0.53–0.87) 0.10
Forearm fat, % 26.5 (19.9–31.4) 25.2 (21.6–39.2) 43.9*† (33.3–54.6) <0.001
Hypertension 0 (0) 19 (100) 20 (100) <0.001
Diabetes 0 (0) 3 (15.8) 11 (55.0) <0.001
Insulin 0 (0) 0 (0) 4 (20) 0.030
Hyperlipidemia 5 (25) 11 (57.9) 18 (90) <0.001
Coronary artery disease 0 (0) 0 (0) 4 (20) 0.030
Prior atrial fibrillation/flutter 0 (0) 3 (15.8) 7 (35) 0.008
OSA 1 (5) 4 (21.1) 12 (60) <0.001
CPAP device 0 (0) 2 (10.5) 7 (35) 0.005
Beta-blocker 0 (0) 6 (31.6) 16 (80) <0.001
CCB 0 (0) 7 (36.8) 11 (55) <0.001
ACE inhibitor/ARB 0 (0) 10 (52.6) 14 (70) <0.001
Loop diuretic 0 (0) 0 (0) 10 (50) <0.001
Thiazide diuretic 0 (0) 3 (15.8) 4 (20) 0.125
Statin 3 (15) 8 (42.1) 14 (70) 0.002
NYHA functional class II 18 (90)
eGFR, ml/min 87.3  12.6 79.5  17.8 71.1  19.9* 0.015
Hemoglobin, g/dl 13.9  1.3 14.0  1.0 12.7  1.1*† <0.001
NT-proBNP, pg/ml 35.0 (17.0–63.5) 65.0 (34.0–127.0) 119.0* (49.0–241.5) 0.002
LV ejection fraction, % 59.6  6.8 59.8  4.5 61.9  5.6 0.388
Tricuspid regurgitant jet velocity, cm/s 199.8  26.8 233.2  40.8‡ 265.5  28.8*† <0.001
Mitral inflow early velocity (E), cm/s 67.4 (54.1–79.4) 75.2 (64.1–84.4) 80.3* (66.5–97.3) 0.035
Septal TD e0 velocity, cm/s 9.6  2.3 8.9  1.9 7.6  2.4* 0.016
Mitral E/septal e0 ratio 6.6 (5.9–8.5) 9.0 (7.0–10.5) 11.9*† (8.4–13.4) <0.001
Values are median (interquartile range), n (%), or mean  SD. *HFpEF versus healthy, adjusted p< 0.05. †HFpEF versus HTN, adjusted p < 0.05. ‡Healthy versus HTN, adjusted
p < 0.05.
ACEi ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CCB ¼ calcium-channel blocker; CPAP ¼ continuous positive airway
pressure; eGFR ¼ estimated glomerular filtration rate; HFpEF ¼ heart failure with preserved ejection fraction; HTN ¼ hypertension; LV ¼ left ventricular;
NT-proBNP ¼ N-terminal pro–brain natriuretic peptide; NYHA ¼ New York Heart Association; OSA ¼ obstructive sleep apnea; TD ¼ tissue Doppler.
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217basis of midrange mitral E/septal e0 ratios of >8 and
elevated NT-proBNP, and 3 were enrolled on the basis
of midrange E/e0 ratios and chronic loop diuretic
agent use.
Demographic and medical history data are pre-
sented in Table 1. Subjects with HFpEF were older,
were more obese, and had typical comorbidities
consistent with the disease, such as hypertension
(100%), diabetes (55%), hyperlipidemia (90%), and
obstructive sleep apnea (60%). Subjects with HFpEF
exhibited higher NT-proBNP and lower hemoglobin
concentrations. The tricuspid regurgitant jet velocitywas higher in subjects with HFpEF, alongside an
increased mitral E/septal e0 ratio. On DEXA, subjects
with HFpEF had marked increases in total body and
forearm fat (Table 1).
CYCLE ERGOMETRIC EXERCISE DATA. Cycle ergo-
metric exercise data are presented in Table 2. Sub-
jects with HFpEF exercised for a significantly shorter
duration than either patients with hypertension or
healthy control subjects. Commensurate with this,
peak VO2 was reduced in subjects with HFpEF
compared with either control group, regardless of
how VO2 is presented (unindexed, indexed to body
TABLE 2 Results of Maximal-Effort Cardiopulmonary Exercise Testing
Healthy (n ¼ 20) HTN (n ¼ 19) HFpEF (n ¼ 20) p Value
Baseline
Heart rate, beats/min 62.7  10.2 67.2  12.6 69.8  9.7 0.127
MAP, mm Hg 97.0  10.0 99.9  10.6 97.5  14.4 0.724
Stroke volume, ml 73.2 (67.5–88.6) 66.4 (62.5–75.3) 83.4 (71.3–97.6) 0.085
Cardiac output, l/min 4.8 (4.2–5.5) 4.3 (3.6–5.9) 6.0 (5.0–6.5) 0.084
VO2, l oxygen/min 0.26  0.04 0.27  0.04 0.27  0.06 0.927
Indexed VO2, ml/kg body weight/min 3.4  0.6 3.3  0.8 2.7  0.5*† 0.003
Indexed VO2, ml/kg leg lean mass/min 15.2  2.3 15.5  2.6 15.3  2.4 0.915
DAVO2, ml oxygen/dl blood 5.4 (4.8–6.4) 6.1 (4.8–7.1) 4.5*† (4.3–5.3) 0.013
PVR, WU 20.9  5.2 22.3  6.2 17.6  4.9† 0.033
PVR index, WU $ m2 40.3  8.6 45.2  12.5 37.6  9.6 0.090
Peak
Heart rate, beats/min 148.7  18.4 136.6  26.6 114.6  24.9*† <0.001
MAP, mm Hg 116.7  12.8 123.8  14.2 122.3  19.7 0.347
Stroke volume, ml 77.5 (65.0–91.4) 67.7 (60.8–79.1) 87.0† (69.8–95.7) 0.027
Cardiac output, l/min 11.5 (10.0–13.8) 9.7 (7.6–11.9) 9.8 (7.5–11.5) 0.079
Arterial oxygen delivery, l oxygen/min 2.1 (1.9–2.6) 1.9 (1.4–2.2) 1.6* (1.2–1.8) 0.016
RER 1.19  0.12 1.17  0.13 1.06  0.13*† 0.004
Arterial lactate, mmol/l 9.4 (7.5–11.8) 7.3 (5.3–9.1) 6.1 (5.1–10.3) 0.066
Venous lactate 7.5  3.2 5.9  2.8 4.4  3.0* 0.014
Borg dyspnea 7.5 (6–9) 7 (5–8) 8 (7.5–9.5) 0.095
Borg fatigue 8 (8–9) 8 (7–9) 8 (6–8) 0.171
Exercise time, min 24.2 (20.1–32.3) 20.0 (13.9–28.5) 5.5*† (3.3–10.8) <0.001
Work rate, W 208.9 (160.1–312.5) 150.0 (100.0–275.0) 25.0*† (19.8–75.0) <0.001
VO2, l oxygen/min 1.90 (1.31–2.31) 1.49 (1.10–1.68) 0.95*† (0.75–1.34) <0.001
% predicted VO2 89.8  19.7 76.9  15.1 64.0  14.1* <0.001
Indexed VO2, ml/min/kg body weight 23.9 (19.9–31.5) 16.8‡ (12.7–20.7) 10.1*† (7.9–14.7) <0.001
Indexed VO2, ml/min/kg leg lean mass 109.0  23.7 83.2  21.9‡ 59.2  16.0*† <0.001
DAVO2, ml oxygen/dl blood 15.8 (14.3–19.1) 14.9 (11.2–17.5) 11.2*† (8.7–13.0) <0.001
Oxygen pulse, ml oxygen/beat 12.4 (10.0–15.2) 10.3 (8.1–14.1) 9.0* (6.8–11.5) 0.004
PVR, WU 10.2 (8.3–11.9) 13.4‡ (10.6–17.3) 12.3 (9.9–17.8) 0.037
PVR index, WU $ m2 19.2 (16.4–22.3) 25.8‡ (21.3–34.0) 27.6* (21.0–35.1) 0.004
Values are mean  SD or median (interquartile range). *HFpEF versus healthy, adjusted p < 0.05. †HFpEF versus HTN, adjusted p < 0.05. ‡Healthy versus HTN, adjusted
p < 0.05.
DAVO2 ¼ arteriovenous oxygen content difference; MAP ¼ mean arterial pressure; PVR ¼ peripheral vascular resistance; RER ¼ respiratory exchange ratio; VO2 ¼ oxygen
consumption; WU ¼ Wood units; other abbreviations as in Table 1.
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218mass, or indexed to leg lean mass). Although the
mean respiratory exchange ratio was lower in the
HFpEF group, comparably increased blood lactate
levels and Borg scores were present in all 3 groups at
peak, supportive of exhaustive effort, particularly
when one considers the older age of the participants
with HFpEF (Table 2) (22).
The CO response to exercise was commensurate
with the rise in VO2 in all groups: for every 1 l of oxygen
consumed per minute, CO increased by 4.5  1.5 l/min
in healthy subjects, 4.5  1.7 l/min in those with hy-
pertension, and 5.5  2.2 l/min in those with HFpEF
(p ¼ 0.173). Although the peak arterial oxygen delivery
was reduced in subjects with HFpEF primarily because
of reduced arterial oxygen content, the change in
arterial oxygen delivery versus the change in VO2 from
baseline to peak exercise was no different betweengroups (p ¼ 0.718) (see the Supplemental Data in the
Supplemental Appendix).
Systemic DAVO2, calculated as the ratio of VO2 to CO
according to the Fick principle, was significantly
lower at peak exercise in patients with HFpEF. Simi-
larly, the oxygen pulse, which is derived from directly
measured variables (oxygen pulse ¼ VO2/heart rate),
was also reduced in patients with HFpEF (Table 2).
FOREARM EXERCISE AND DmO2. Forearm exercise
data are presented in Table 3. Exhaustive effort was
achieved in all groups, as evidenced by similar rela-
tive effort at peak exertion (%MVC) and similar total
work performed during the final 20 s. Peak forearm
VO2 was not different among groups.
Supplemental oxygen (FIO2 ¼ 1.00) increased fore-
arm maximal VO2, compared with FIO2 ¼ 0.21, con-
firming that maximal forearm VO2 was limited by
TABLE 3 Forearm Exercise Parameters During Maximal Effort
Room Air Transients 100% Oxygen Transients
RA
Transients
100%
Transients p Value
Healthy
(n ¼ 20)
HTN
(n ¼ 17)
HFpEF
(n ¼ 18) p Value
Healthy
(n ¼ 20)
HTN
(n ¼ 17)
HFpEF
(n ¼ 18) p Value
Exercise parameters at
peak effort
% MVC 71.7
(62.2–79.4)
70.4
(58.4–76.3)
72.6
(64.3–79.0)
0.789 67.7
(61.4–78.7)
66.9
(56.3–71.7)
66.5
(62.2–79.4)
0.560 72.2
(62.6–78.4)
66.7
(60.2–77.9)
0.120
Work performed
during last
20 s, N $ s
1,615.4 
589.6
1,581.8 
717.8
1,326.4 
584.0
0.296 1,500.4 
421.3
1,559.8 
600.9
1,221.8 
427.8
0.084 1,506.6 
634.5
1,428.6 
502.8
0.027
Venous lactate,
mmol/l
3.0
(2.5–3.3)
3.2
(2.2–3.4)
2.1*
(1.9–2.9)
0.049 2.2  0.6 2.1  0.6 1.9  0.6 0.222 2.8
(2.1–3.2)
2.1
(1.6–2.6)
<0.001‡
Brachial blood
flow (ml/min)
192.3
(143.1–331.6)
212.8
(175.5–249.8)
219.4
(142.3–296.3)
0.984 201.5
(151.5–292.1)
224.2
(170.1–296.8)
204.9
(145.7–299.0)
0.910 212.8
(144.0–297.0)
207.5
(163.2–296.8)
0.254
Brachial blood flow
(ml/min/kg forearm
lean mass)
268.0 
103.0
261.1 
90.3
313.9 
106.8
0.208 270.9 
90.8
278.8 
104.1
316.4 
101.8
0.319 281.4 
101.5
288.4 
99.2
0.414
Blood gas
measurements
at maximal effort
Arterial PO2, mm Hg 85.9  14.3 85.6  8.4 77.5  8.8 0.031 530.0
(501.0–553.0)
505.0
(462.0–522.0)
483.5
(385.5–592.5)
0.359 84.0
(75.0–89.0)
507.5
(461.0–553.0)
<0.001
Arterial oxygen
content,
ml oxygen/dl blood
18.4  1.9 18.6  1.8 16.5*†  1.3 <0.001 20.3  1.9 20.2  1.8 18.1*†  1.5 <0.001 17.9  1.9 19.6  2.0 <0.001
Arterial oxygen
delivery,
ml oxygen/min
39.4
(23.3–62.6)
38.6
(40.0–50.1)
32.9
(22.1–43.5)
0.438 46.4  22.4 48.1  17.4 41.5  20.3 0.614 38.3
(23.9–50.1)
43.0
(29.6–58.7)
<0.001
Venous PO2, mm Hg 23.2  3.7 24.2  4.0 24.6  4.8 0.551 26.2  3.7 26.4  4.4 27.6  4.1 0.571 24.0  4.1 26.7  4.0 <0.001
Venous oxygen
content,
ml oxygen/dl blood
6.6
(6.1–7.5)
7.3
(6.6–8.5)
6.4
(5.9–7.1)
0.101 8.4  2.0 9.0  1.4 8.2  1.8 0.321 6.7
(6.2–7.9)
8.4
(7.8–9.6)
<0.001
DAVO2, ml oxygen/
dl blood
11.6
(10.9–12.7)
11.1
(9.8–12.1)
9.6*
(9.1–11.2)
0.005 11.9  1.6 11.2  2.1 9.9*  1.8 0.011 11.1
(9.7–12.3)
11.3
(9.6–12.6)
0.131
Forearm VO2, ml
oxygen/min
21.6
(15.9–38.6)
21.3
(16.9–33.4)
19.0
(13.1–24.3)
0.216 26.0
16.6–34.5)
25.9
(19.1–37.3)
20.2
(13.1–28.4)
0.438 21.2
(15.3–27.4)
23.3
(16.6–34.5)
0.0499
Forearm VO2, ml/
min/kg
forearm lean mass
31.5  12.9 28.4  9.2 29.5  10.8 0.668 31.8  11.7 31.5  11.8 31.5  10.8 0.996 29.8  11.0 31.6  11.3 0.076
Diffusional conductance
for oxygen
Mean capillary DmO2
(ml/min/mm Hg)
0.54
(0.42–1.04)
0.63
(0.46–0.70)
0.48
(0.32–0.62)
0.140 0.55
(0.37–0.81)
0.57
(0.42–0.75)
0.46
(0.27–0.65)
0.250 0.56
(0.41–0.74)
0.49
(0.40–0.73)
0.018
Mean capillary
DmO2/kg
forearm lean mass
(ml/min/mmHg/kg)
0.83  0.34 0.73  0.23 0.77  0.30 0.565 0.70  0.26 0.72  0.26 0.69  0.24 0.915 0.78  0.29 0.70  0.25 0.009
Mean capillary PO2
(mm Hg)
37.5  4.4 38.0  4.6 37.9  4.3 0.932 46.3
(42.3–48.4)
44.1
(40.2–49.6)
47.8
(42.6–50.0)
0.781 37.8
(35.1–40.2)
46.2
(42.3–49.5)
<0.001
Values are median (interquartile range) or mean  SD. RA and 100% represent overall group summary statistics for the transients at the given inspired oxygen concentrations. *HFpEF versus healthy,
adjusted p < 0.05. †HFpEF versus HTN, adjusted p < 0.05. ‡The decrease in lactate at peak effort with oxygen, compared with RA, was significantly greater in healthy individuals than subjects with HFpEF.
DmO2 ¼ skeletal muscle diffusional conductance for oxygen; MVC ¼ maximal voluntary contraction force; PO2 ¼ partial pressure of oxygen; other abbreviations as in Tables 1 and 2.
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219oxygen delivery as opposed to mitochondrial oxida-
tive capacity during the room-air transients. There
was no difference in the VO2 response to 100% oxygen
between the groups. Brachial blood flow was no
different between groups and was unaffected by
supplemental oxygen.
Forearm DmO2 was no different between groups,
even when indexed to forearm lean muscle mass
(Table 3, Supplemental Figure 1). Forearm DmO2correlated with systemic peak VO2 on cycle ergometry
(r ¼ 0.51; p ¼ 0.0001). As with cycle ergometry,
forearm DAVO2, which was directly measured from
arterial and venous blood gases, was lower in patients
with HFpEF.
RELATIONSHIP BETWEEN DAVO2 AND BLOOD
FLOW. Because larger muscle mass necessitates
greater blood flow, we analyzed the relationship be-
tween DAVO2 and estimated brachial blood flow
FIGURE 2 DAVO2 Versus Brachial Flow
The relationship between arteriovenous oxygen content difference (DAVO2) and estimated brachial flow, indexed to forearm lean mass, during
forearm exercise. Data are displayed as marginal means with 95% confidence intervals. HFpEF ¼ heart failure with preserved ejection
fraction; HTN ¼ hypertension.
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220indexed to forearm lean mass, using more than 800
data points obtained during all forearm exercise
studies, and computed estimated marginal means at
various blood flow rates. We found a significant dif-
ference in this relationship in subjects with HFpEF,
with lower DAVO2 for any given estimated indexed
blood flow (Figure 2) (overall p < 0.001), and a lower
slope describing the rate of rise in DAVO2 as blood flow
increases (slope comparison: HFpEF vs. hyperten-
sion, p ¼ 0.010; HFpEF vs. healthy, p ¼ 0.009; healthy
vs. hypertension, p ¼ 1.0).
A similar analysis was performed comparing sys-
temic DAVO2 to estimated CO, indexed to leg lean
mass, during cycle ergometry. Because few subjects
with HFpEF were able to complete the fourth stage of
exercise, analyses were restricted to the first 3 stages
of exercise to ensure representation of subjects with
HFpEF at each time point. In these analyses, subjects
with HFpEF tended to have lower DAVO2 for any given
estimated indexed CO (Supplemental Figure 2)
(p ¼ 0.081).
MODELS PREDICTING DAVO2. Univariate predictors
of the regional and systemic DAVO2 are presented in
Table 4. Multivariate linear models were created to
determine the independent correlates of the forearmarteriovenous oxygen content relationship for all
subjects (Table 4). For any given DmO2 and brachial
blood flow, forearm tissue composition was a signifi-
cant predictor of DAVO2, with an increase in forearm
fat correlating with a reduced DAVO2.
Similar models were then created for systemic
DAVO2, in which local determinants were substituted
for their systemic counterparts (i.e., CO was
substituted for brachial flow, and whole-body fat was
substituted for forearm fat). In these models, body
composition significantly predicted systemic DAVO2,
with a negative correlation seen for body fat mass,
while lean mass was positively correlated with sys-
temic DAVO2.
RELATIONSHIP BETWEEN FOREARM VO2 AND CYCLE
ERGOMETRY VO2. Despite no difference in peak
forearm VO2 among groups, forearm VO2 was moder-
ately correlated with cycle ergometric peak VO2
(r ¼ 0.53; p < 0.0001). Using linear regression, peak
forearm VO2 predicted 36% of the variability in cycle
ergometric peak VO2 (Figure 3A) (standardized
b ¼ 0.61; p < 0.001; model R2 ¼ 0.36).
We then explored differences in this relationship
among groups. Formal interaction testing revealed no
differences in the slope of the relationship between
TABLE 4 Univariate and Multivariate Models for Predictors of Regional and
Systemic DAVO2
Forearm DAVO2
Univariate
Systemic DAVO2
Standardized b p Value Standardized b p Value
Univariate
Age –0.23 0.081 Age –0.27 0.055
Male 0.24 0.075 Male 0.39 0.005
HFpEF –0.43 0.001 HFpEF –0.50 <0.001
Forearm fat –0.32 0.014 Body fat mass,
kg
–0.60 <0.001
Forearm lean mass 0.21 0.110 Body lean
mass
0.11 0.438
Forearm % fat –0.36 0.006 Body % fat –0.62 <0.001
Forearm DmO2 0.45 <0.001 Forearm
DmO2
0.18 0.220
Peak brachial flow –0.003 0.984 Peak cardiac
output
–0.19 0.185
Multivariate Model
R2 ¼ 0.74
Model
R2 ¼ 0.69
Age –0.14 0.066 Age –0.32 0.002
Forearm fat –0.21 0.005 HFpEF –0.22 0.028
Peak brachial flow –1.30 <0.001 Body fat mass –0.54 <0.001
DmO2 1.45 <0.001 Body lean mass 0.57 <0.001
Peak cardiac
output
–0.75 <0.001
Abbreviations as in Tables 1 to 3.
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221forearm and cycle VO2; however, there were differ-
ences in the main effects (i.e., group). For any given
forearm VO2, the predicted cycle ergometric VO2 was
lower in subjects with HFpEF compared with healthy
controls, with subjects with hypertension being
roughly in the middle of the other groups (Figure 3B).
Addition of the grouping variable increased the
amount of variability in cycle ergometric VO2
explained by the covariates (model adjusted
R2 ¼ 0.55; p < 0.001).
DISCUSSION
The main findings of this study are as follows: 1)
subjects with HFpEF demonstrated a marked reduc-
tion in cycle ergometric exercise capacity; 2) because
CO increased in accordance with VO2 (an increase of
w5 l/1 l of oxygen consumed), our findings suggest
that abnormalities in DAVO2 play a key role in limiting
exercise capacity; 3) in line with this, for any given
increase in forearm blood flow during local exercise,
subjects with HFpEF demonstrated lower forearm
DAVO2 with a shallower rate of rise as flow increased;
4) however, forearm DmO2 was not different between
groups and thus cannot explain the reduction in
forearm DAVO2; 5) after controlling for blood flow, the
degree of adiposity, measured using whole-body
DEXA, was significantly associated with both the
local and systemic DAVO2; and 6) physiological de-
terminants of local oxygen utilization determined
during our forearm exercise experiments were able to
predict more than one-third of the variability in sys-
temic peak VO2, suggesting that peripheral limitations
to exercise account for an important proportion of
systemic aerobic capacity.
Our results are in line with those of prior studies
that demonstrated the importance of DAVO2 in
determining exercise capacity in subjects with HFpEF
(5,6,23). However, DAVO2 is a complex metric, influ-
enced by: 1) blood flow, arterial oxygen content, and
hemoglobin oxygen binding characteristics (convec-
tive oxygen transport); and 2) the ability of oxygen to
cross the capillary membrane in accordance with the
PO2 gradient between the microvasculature and the
mitochondria (diffusive oxygen transport). All other
things being equal, lower skeletal muscle blood flow
might be expected to increase DAVO2 because of
longer red blood cell capillary transit times, and vice
versa (7,24). Consistent with this notion, we found an
inverse relationship between blood flow and DAVO2
during both small- and large-muscle exercise, high-
lighting the complexity in assessing DAVO2 in isola-
tion and demonstrating that the Fick determinants of
VO2 (DAVO2 and flow) are not independent (7,24).In contrast, DmO2 across the skeletal muscle
capillary membrane is expressed per unit of time
(milliliters of oxygen per minute per millimeter of
mercury) and therefore is independent of differences
in capillary transit time (9). Recently, an elegant
modeling study raised the possibility for reduced
DmO2 in subjects with HFpEF (7). That study focused
on estimations of DmO2 based on pulmonary artery
blood gas samples obtained during cycle exercise.
Although intriguing, large-muscle exercise, such as
cycle ergometry, might be influenced by central (i.e.,
cardiac) limitations, reaching a “ceiling” on skeletal
muscle oxygen supply (9). Moreover, as the in-
vestigators noted, the degree to which mixed venous
blood in the pulmonary artery reflects the blood
draining from the skeletal muscle may be variable
between patients with HFpEF and control subjects,
in part because of the abnormalities in systemic
blood flow distribution and the vasodilatory reserve
in patients with HFpEF (25). In contrast, in the pre-
sent investigation, we estimated DmO2 during fore-
arm exercise, a small-muscle modality that is not
dependent upon peak CO, and we used local deep
venous blood sampling, leading to measurements
that focus exclusively on the factors driving local
skeletal muscle oxygen utilization in the forearm. In
our measurements, we did not find a reduction in
FIGURE 3 Relationship Between Local Exercise and Systemic Aerobic Capacity
Cycle ergometric oxygen consumption (VO2) versus forearm VO2. Among all subjects, forearm VO2 significantly correlated with peak VO2 on
cycle ergometry (model R2 ¼ 0.36; left). For any given forearm VO2, subjects with HFpEF had lower peak VO2 on cycle ergometry (model
R2 ¼ 0.55; right). Abbreviations as in Figure 2.
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222forearm DmO2 during maximal-effort forearm
exercise.
Our study answers the central question as to why
subjects with HFpEF do not simply extract more ox-
ygen to balance the forearm DAVO2 during exercise:
given that forearm DmO2 was the same between
groups, increasing forearm DAVO2 would drive mean
capillary PO2 lower in subjects with HFpEF. By Fick’s
law of diffusion, lower mean capillary PO2 would
actually reduce VO2 for a given DmO2 (26) by
decreasing mitochondrial oxygen availability. This
imposes a limit below which capillary oxygen content
cannot be reduced. Strategies that either increase
arterial oxygen content (i.e., increase hemoglobin)
such that more total oxygen can be extracted for any
given DmO2 or increase forearm DmO2 and allow
greater fractional extraction (or ideally both; see the
following discussion) need to be undertaken to
improve DAVO2 in patients with HFpEF (27).
Interestingly, we found that body composition,
particularly the degree of adiposity, was correlated
with DAVO2, with increasing fat associated with
reduced DAVO2. Three possible explanations exist for
this finding. First, the adipose tissue within and
around the myocytes could “steal” blood away from
the exercising skeletal muscle (28,29). As the fat isless metabolically active, especially during exercise,
the adipocytes would extract less oxygen than exer-
cising muscle for any given flow, leading to a greater
venous oxygen content in the draining vein. Second,
the adipose tissue may have an impact on skeletal
muscle metabolism and the mitochondria (29).
Obesity is associated with impairments in skeletal
muscle fuel utilization (30–32), mitochondrial content
(33,34), and an increase in inflammation and reactive
oxygen species (3,35,36), which can also decrease
mitochondrial function. The lower slope of the rela-
tionship between the change in forearm DAVO2 as a
function of indexed brachial flow in subjects with
HFpEF suggests abnormalities in oxygen utilization
at the skeletal muscle (37,38). Third, obesity, as a
source of chronic inflammation, may be an important
contributor to the anemia commonly seen in HFpEF
(39,40), leading to a lower arterial content, which
may influence DAVO2. Although erythropoiesis-
stimulating agents increase hemoglobin concentra-
tion in patients with HFpEF, their use did not
improve submaximal exercise capacity, as measured
using the 6-min walk test (41), though changes in
peak VO2 were not assessed.
Perhaps the links between adiposity, mitochon-
drial function, and aerobic capacity in patients with
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223HFpEF explain recent findings in clinical trials that: 1)
adiposity inversely correlates with peak aerobic ca-
pacity in subjects with HFpEF (42); 2) weight loss
decreases systemic inflammation (43); and 3) when
combined with exercise training, weight loss leads to
additive benefits in increasing aerobic capacity in
subjects with HFpEF beyond those garnered from
exercise alone (44). Our findings may help reinforce
the importance of weight loss and exercise training in
patients with HFpEF and point toward a novel
mechanistic link between obesity and reduced aero-
bic capacity in patients with HFpEF.
Peak forearm VO2 significantly correlated with
whole-body aerobic capacity, even though forearm
VO2 was not different among groups, whereas cycle
ergometric peak VO2 was. Notwithstanding this
finding, that small-muscle exercise was able to pre-
dict more than a third of the variability in whole-body
exercise is noteworthy, reinforcing the importance of
local peripheral factors on systemic aerobic capacity.
However, for any given forearm VO2, cycle ergometric
peak VO2 was systematically lower in subjects with
HFpEF, suggesting that additional factors not
addressed in the small-muscle forearm exercise
(including cardiac abnormalities) further constrain
VO2 in subjects with HFpEF.
We did not measure central filling pressures in our
studies, and it is possible that although the CO-to-VO2
relationship was preserved in patients with HFpEF
(w5 l of CO/1 l of oxygen consumed), the increase in
CO came at the cost of higher filling pressures and
shortness of breath (4). It is also possible that other
noncardiovascular limitations to exercise, such as
increased work of breathing, might be present during
whole-body exercise that requires greater muscle
mass. Of note, the well-known effect of excess leg
weight in obesity could not explain the additional
decrement in systemic VO2, because the excess
weight in subjects with HFpEF would be expected to
increase systemic VO2 for any given forearm VO2
because of the increased work required to move the
larger mass (45).
It is tempting to speculate that simply a reduction
in absolute muscle mass could explain many of our
findings. However, we found no difference in the
absolute amount of lean mass across groups (data not
shown) on DEXA (29,38), and the differences in
whole-body exercise persisted, even when indexing
systemic VO2 to lean leg mass (38,42). Instead, the
amount of fat mass, and the ratio of fat mass to totalmass (which takes lean mass into account), were
strikingly divergent among groups (29,38,42).
Importantly, we show that the degree of adiposity
correlated with the reductions in DAVO2.
Although cycle ergometric VO2 was markedly
different among groups, we did not find a difference
in forearm VO2. This was unexpected, as prior work
suggested abnormalities in blood flow distribution
during small-muscle exercise in patients with HFpEF
(46), along with reduced grip strength, which was
recapitulated in our study (47). One would have ex-
pected this to translate into lower forearm VO2;
however, this was not found. Instead, the reduced
DAVO2 across the forearm at peak exercise was
counterbalanced by numerically greater (though not
statistically significant) brachial blood flow, keeping
forearm VO2 relatively preserved. Importantly, our
estimates of forearm VO2, brachial blood flow, and
forearm DAVO2 are similar in magnitude to those
observed in prior work (15,18). Our data are at odds
with prior work in patients with HFpEF that
demonstrated reduced blood flow redistribution to
exercising muscle during small-muscle mass move-
ments (46), perhaps because of differences in the
muscle bed studied and/or whether the exercise
paradigm was isotonic rather than isometric as
herein.
We found that DAVO2 was reduced during forearm
exercise, as it was systemically during whole-body
exercise, but the absence of any concomitant
decrease in forearm DmO2 removed compromised
oxygen diffusion as a candidate mechanism to
explain the reduced forearm DAVO2. Although previ-
ous work on DmO2 has focused largely on the legs
(9,20), our forearm technique allowed DmO2 mea-
surements in a much greater number of subjects
because of its less invasive nature. How leg DmO2
compares with forearm measurements in the same
subject is unknown and should be the focus of future
work. Indeed, in the only prior study of local DmO2 in
heart failure, Esposito et al. (9) measured DmO2 dur-
ing leg extension exercise, estimating DmO2 to be
5.1 ml oxygen/min/mm Hg/kg leg muscle, which is a
much greater value than we observed across the
forearm. This suggests that differences exist between
the forearm muscles and those involved in locomo-
tion, which is certainly not unexpected. Regardless,
our data argue against a circulating factor that
impairs microcirculatory function throughout the
body.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with HFpEF are markedly limited in terms of
functional capacity. Although cardiac abnormalities
have been described, our work suggests that
additional “peripheral” factors further conspire to
constrain exercise capacity. Here, we found that
although DAVO2 was reduced in patients with HFpEF
during both peak whole-body and local (forearm)
exercise, forearm DmO2 was no different compared
with both healthy subjects and those with hyperten-
sion and is therefore unable to explain the reduced
forearm DAVO2 seen in patients with HFpEF. Yet
DAVO2 increased more slowly in subjects with HFpEF,
suggesting intrinsic abnormalities within the skeletal
muscle itself. We found strong associations between
the degree of adiposity and DAVO2, suggesting that
adipocytes may play a detrimental role in limiting
exercise capacity.
TRANSLATIONAL OUTLOOK: Accumulating
evidence suggests that the adipose tissue may play an
active role in limiting exercise capacity in patients with
HFpEF. Future research investigating the potential
mechanism(s) through which the adipocytes may
negatively affect skeletal muscle function is
warranted.
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224STUDY LIMITATIONS. We used an isometric exercise
protocol consisting of forearm handgrip exercise, as
opposed to dynamic exercise such as arm cranking.
This may have led to differences in the peak forearm
VO2 measurements achieved in our study compared
with other studies (48) and may also have affected
our DmO2 estimations (48). However, handgrip ex-
ercise more likely reflects the type of forearm exercise
encountered by patients with HFpEF during routine
activities of daily living, as opposed to arm cranking.
We recognize, though, that the type of exercise and
its characteristics (e.g., duty cycle) could affect fore-
arm DmO2 estimations (49). Future studies on DmO2
and oxygen transport in patients with HFpEF should
consider the exercise paradigm, in addition to the
muscle bed interrogated, to reach the most clinically
relevant findings.
We did not randomize the order in which sub-
jects exercised while breathing FIO2 ¼ 0.21 versus
FIO2 ¼ 1.00. Consequently, the decrease in work
performed during the FIO2 ¼ 1.0 transients may
have been due to fatigue, as these represented the
average of the third and fourth exercise bouts.
However, that forearm peak VO2 increased with
FIO2 ¼ 1.00, despite the lower work load, supports
the contention that maximal forearm VO2 was
reached during FIO2 ¼ 0.21. Finally, our DmO2
measurements assume homogeneity of VO2 and flow
within the exercising muscle; however, we now
know that this is not always the case (50). When
better techniques become available, future studies
examining DmO2 during exercise will be needed to
clarify the physiological importance of flow and VO2
heterogeneity within the muscle in subjects with
HFpEF.
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